Saturday 17 October 2026 Export ABSI’s income statement to Excel — free account

Absci Corporation

Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024. In the quarter to June 2026, revenue fell 46.4%, EPS grew 12.5%, free cash flow fell 71.7% and total debt fell 93.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.25 0.63 −7.09%

Follow ABSI

Alert me

Market cap: $1.5B
P/E: 0.0×
Fwd P/E: −8.0×
Dividend yield: —
F-score: 3/9
Altman Z: 5.50
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.93

Total sells 0.13

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	1	1	—	1	1	—	—	—	—
Sell	—	—	—	2	—	—	—	—	—	—	—	—

Insider Ownership 5.95%

Capital & Financial Ratios $m

Market Cap 1,520.00

Revenue 1.56

Net Income (121.08)

Free Cash Flow (108.80)

Net Debt (200.99)

Current Ratio 10.63

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (8.03)

P/S ratio 832.25

P/B ratio 5.28

Past 5Y EPS Growth —

This Y EPS Growth 4.95%

Next Y EPS Growth 9.42%

Next Y revenue growth 39.04%

Next 5Y EPS Growth 11.87%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 95.14%

10-year low 10-year high

P/B against its own 10 years 93.45%

10-year low 10-year high

EV/Sales against its own 10 years 94.91%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	114	128	144	201
Receivables	2	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	121	134	150	208

	2023	2024	2025	Q'26
Payables	2	10	19	16
ST’ Debt	3	3	1	0
Other	13	13	—	—
	30	29	23	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	(10.14%)	(21.31%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	23.11%	(11.62%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	0	1	3
’24	1	1	2	1	5
’23	1	3	1	0	6
’22	1	1	2	2	6
’21	1	1	2	1	5
’20	1	1	1	3	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(28)	—	—	—
’25	(22)	(17)	(25)	(29)	(93)
’24	(18)	(17)	(21)	(17)	(72)
’23	(20)	(19)	(10)	(15)	(65)
’22	(21)	(23)	(19)	(19)	(81)
’21	(7)	(14)	(22)	(17)	(61)
’20	(2)	(3)	(3)	(3)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(28)	—	—	—
’25	(22)	(16)	(26)	(29)	(93)
’24	(18)	(17)	(21)	(16)	(72)
’23	(20)	(19)	(11)	(15)	(65)
’22	(28)	(26)	(24)	(19)	(97)
’21	(14)	(32)	(27)	(25)	(99)
’20	(3)	(4)	(3)	(3)	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.19)	(0.21)	—	—	—
’25	(0.21)	(0.24)	(0.20)	(0.20)	(0.84)
’24	(0.22)	(0.22)	(0.24)	(0.25)	(0.94)
’23	(0.26)	(0.45)	(0.24)	(0.25)	(1.20)
’22	(0.33)	(0.32)	(0.30)	(0.21)	(1.15)
’21	(0.65)	(2.39)	(0.33)	(0.28)	(2.08)
’20	(0.17)	(0.20)	(0.25)	(0.31)	(0.93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	7.60	1.94	1.11	2.45	2.01	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	31.53	9.68	5.47	6.72	6.33
People
People	Employees	—	—	—	—	169	212	193	156	157	140
	Revenue/emp, $m	—	—	—	0.00	0.03	0.02	0.03	0.04	0.03	0.02
Income, $m
Income, $m	Revenue	—	—	—	2	5	5	6	6	5	3
	Gross margin, %	—	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	—	(7)	(14)	(110)	(105)	(110)	(103)	(115)
	EBT margin, %	—	—	—	(319.61)	(300.27)	(2,297.34)	(1,833.39)	(1,931.90)	(2,272.52)	(4,111.21)
	Net income	—	0	—	(7)	(14)	(101)	(105)	(111)	(103)	(115)
	Depreciation	—	—	—	0	1	7	13	35	13	12
Per share, $
Per share, $	Revenue	—	—	—	0.14	0.31	0.10	0.06	0.06	0.04	0.02
	Earnings	—	—	—	(0.43)	(0.93)	(2.08)	(1.15)	(1.20)	(0.94)	(0.84)
	Cash flow	—	—	—	(0.40)	(0.71)	(1.22)	(0.90)	(0.70)	(0.66)	(0.68)
	Capex	—	—	—	(0.07)	(0.14)	(0.77)	(0.18)	(0.01)	0.00	0.00
	Free cash flow	—	—	—	(0.47)	(0.85)	(1.99)	(1.07)	(0.71)	(0.65)	(0.68)
	Book value	—	—	—	0.76	4.32	7.37	3.02	1.91	1.62	1.39
	Shares, m	—	—	—	15	15	50	91	92	110	137
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	70.08	70.08	85.20	35.72	59.39	63.70	170.48
	P/B	—	—	—	0.00	0.00	1.11	0.75	1.93	1.61	2.52
	EV/Sales	—	—	—	78.96	78.96	31.60	6.53	40.86	36.27	119.28
	EV/FCF	—	—	—	(8.13)	(8.13)	(1.53)	(0.39)	(3.58)	(2.29)	(3.60)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(6)	(11)	(61)	(81)	(65)	(72)	(93)
	Capex	—	—	—	(1)	(2)	(38)	(16)	(1)	1	0
	Free cash flow	—	—	—	(7)	(13)	(99)	(97)	(65)	(72)	(93)
Balance, $m
Balance, $m	Working capital	—	—	—	10	63	239	157	91	105	127
	Total debt	—	—	—	4	8	7	12	8	4	1
	Net debt	—	—	—	(9)	(62)	(256)	(168)	(106)	(124)	(143)
	Shareholders’ equity	—	—	—	12	67	366	274	176	179	189
Returns, %
Returns, %	ROA	—	—	—	(245.19)	(91.58)	(40.11)	(28.08)	(41.08)	(47.86)	(53.59)
	ROIC	—	—	—	(162.00)	(168.01)	(42.83)	(62.56)	(102.78)	(124.30)	(163.37)
	ROE	—	—	—	36.56	75.76	(74.63)	(32.76)	(49.08)	(58.04)	(62.50)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−46.23% (below 0%: shrinking)	n/m	+15.05% (above 0%: growing)	100.00%	(1,472.25%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)
IMCR Immunocore Holdings PLC Sponsored ADR	$1.5B	— (loss-making)	208×	+18.34% (above 0%: growing)	n/m	−40.74% (below 0%: shrinking)	99.06%	(2.58%)	Compare
RARE Ultragenyx Pharmaceutical Inc.	$1.5B	— (loss-making)	— (loss-making)	+28.14% (above 0%: growing)	n/m	+12.50% (above 0%: growing)	84.11%	(35.05%)	Compare
ANAB AnaptysBio, Inc.	$1.5B	— (loss-making)	220×	−7.98% (below 0%: shrinking)	n/m	−141.60% (below 0%: shrinking)	100.00%	(135.53%)	Compare
Median of peers	$1.5B	—	—	+1.51%	—	−14.12%	99.53%	(18.81%)

All 614 Biotechnology stocks →

Absci Corporation (ABSI) key facts

Concern: Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024.
Absci Corporation (ABSI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ABSI traded at $8.25, a market capitalization of $1.5 billion.
Return on equity was −62.5% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 5.50 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.